We are happy to announce Agendia has been named one of the Top 10 Precision Oncology Solutions Providers in 2024.
Agendia is proud to be a part of the precision medicine movement with our genomic tests, MammaPrint® and BluePrint®, for early-stage breast cancer.
To read more about the recognition, our fellow nominees, and trends in the global precision medicine market, visit Healthcare Tech Outlook.